AI Explained: A Guide for Executives

From boardrooms to factory floors, everyone’s talking about Artificial Intelligence, but is it more than a buzzword? This guide by Accenture explains its revolutionary implications and what execs should be doing today.

Context:

General-purpose technologies are a big deal; they cause disruption not only through direct contribution to society, but also through the way their spill-over effects enable a vast range of complementary innovations.

In the UK, a major government-commissioned report estimates AI could unlock £630 billion for the country’s economy.

Contents include:
  • What is AI anyway?
  • What businesses need to do now
  • The risks involved
  • The bigger picture




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Click here to download this insight
Embracing the Human-AI Partne...

Singtel faces a rapidly changing environment as geopolitics, customer expectations and AI reshape its business. In discussion with Criticaleye Senior Editor Bridgette Hall, Group Chief People & Sustainability Office...

Click here to download this insight
Reaching New Heights at Guoco...

After four years in the Group CFO role at one of Singapore’s most prominent real estate developers, GuocoLand Group, Andrew Chew talks to Jacob Ambrose Willson about stepping up from regional CFO to Group, managin...

Click here to download this insight
The AI-led HR Revolution at V...

Victrex’s Group HR Director Jilly Atherton has brought together talent planning, leadership development and digital innovation to support a fast-changing global business, using AI where it adds real value without ...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 477




Aldermore Group AlixPartners NatWest Group Workday Concentrix Accenture NATS Hitachi Solutions Legal & General E.ON UK Worldpay British Land Google Salesforce Eightfold AI Lightsource bp Drax Group plc London Stock Exchange Group FTSE Women Leaders Review Palo Alto Networks Rolls-Royce IBM Consulting GlaxoSmithKline plc